Chargement en cours...
Insulin degludec as an ultralong-acting basal insulin once a day: a systematic review
BACKGROUND: Insulin degludec (IDeg) is a neutral, ultralong-acting new generation basal insulin analog developed by NovoNordisk currently in Phase III clinical development. IDeg offers a duration of action of more than 42 hours in adults, much longer than current basal insulin formulations. OBJECTIV...
Enregistré dans:
| Auteurs principaux: | , , |
|---|---|
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Dove Medical Press
2012
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3402007/ https://ncbi.nlm.nih.gov/pubmed/22826637 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DMSO.S21979 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|